Please ensure Javascript is enabled for purposes of website accessibility

Coronavirus Vaccine Developers Rise After Fauci's Comments

By Eric Volkman - Jul 17, 2020 at 6:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

America's highest-profile medical professional waxes optimistic on the potential for a "safe and effective" vaccine by 2021.

In an interview with Facebook CEO Mark Zuckerberg on Thursday afternoon, Dr. Anthony Fauci expressed strong hope that at least one useful coronavirus vaccine candidate will be available for widespread use within months. 

"[W]e should know as we get into the mid to late fall, early winter, but probably late fall, whether we have candidates that really are safe and effective," said Fauci, director of the National Institute of Allergy and Infectious Diseases.

Gloved hands holding a vial of medicine.

Image source: Getty Images.

"If that's the case, by the time we get to the end of this year, the beginning of calendar year 2021, we may have vaccine, one or more candidate, that is actually safe and effective," he added.

This helped lift the stocks of the developers of leading vaccine candidates at or near double-digit rates on Friday, well outpacing the gains of the top equity indexes. Shares of Moderna (MRNA -0.37%) shot nearly 15% higher, while Novavax gained almost 17%, and the stock of Inovio Pharmaceuticals recorded a gain that was just below 10%.

Of the three, Moderna is considered by many to be the leader in the coronavirus vaccine race. Fauci has expressed hope based on the phase 1 clinical trial results for its mRNA-1273 announced on Tuesday. According to him, Moderna's data "really look quite good. There were no serious adverse events."

Fauci's frequently blunt and sobering opinions on the coronavirus outbreak have met with some resistance from the White House, since at times they clash with its ambitions to reopen the economy. Yet he is widely respected by many healthcare professionals and a large share of the public.

Another factor lifting coronavirus vaccine makers Friday was the news that the European Union is already trying to arrange purchases of potential vaccines from several developers. Moderna is among these companies.

 

Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to its CEO, Mark Zuckerberg, is a member of The Motley Fool's board of directors. Eric Volkman owns shares of Facebook. The Motley Fool owns shares of and recommends Facebook. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$41.47 (2.80%) $1.13
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$2.63 (6.91%) $0.17
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$171.18 (-0.37%) $0.63
Meta Platforms, Inc. Stock Quote
Meta Platforms, Inc.
META
$180.50 (1.70%) $3.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.